Sreeharsha Gurrapu is a post-doctoral fellow. Sreeharsha Gurrapu received his Ph.D. in Molecular Medicine from the lab of Dr. Luca Tamagnone at the University of Turin, Italy. During his Ph.D. studies, he focused on understanding the role of cellular guidance cues called semaphorins and plexins in cancer. His research as a doctoral student led to the identification of novel signaling mechanisms activated by Semaphorin4C that promoted breast cancer proliferation and Epithelial-to-Mesenchymal Transition (EMT) in luminal type breast cancer. In addition, he identified a reverse signaling mechanism, in which Semaphorin4C interacts with TGF-Beta and BMP family members to enhance metastasis in triple-negative breast cancer and prostate cancer. As a co-author, he also identified a role for Plexin D1 in promoting EMT through Notch signaling in prostate and breast cancer. In the current lab, he is working on developing novel genetic screens, niche labeled scRNAseq, and scATACseq analysis in the mouse that enable the identification of key genes of the innate immune system that promote immune evasion and reactivation from dormancy. His major goal is to identify the mechanisms that enable cancer cells to evade the immune system and drug resistance during clinical latency and to target these mechanisms to improve the efficacy of immunotherapy in the adjuvant setting.